Early Parkinson’s Disease Phenotypes Tailored by Personality,Behavior,and Motor Symptoms

Abstract

Background:

Previous studies described a parkinsonian personality characterized as rigid, introverted, and cautious; however, little is known about personality traits in de novo Parkinson’s disease (PD) patients and their relationships with motor and neuropsychiatric symptoms.

Objective:

To investigate personality in de novo PD and explore its relationship with PD symptoms.

Methods:

Using Cloninger’s biosocial model, we assessed personality in 193 de novo PD patients. Motor and non-motor symptoms were measured using several validated scales. Cluster analysis was conducted to investigate the interrelationship of personality traits, motor, and non-motor symptoms.

Results:

PD patients showed low novelty seeking, high harm avoidance, and normal reward dependence and persistence scores. Harm avoidance was positively correlated with the severity of depression, anxiety, and apathy (r_s = [0.435, 0.676], p < 0.001) and negatively correlated with quality of life (r_s = –0.492, p < 0.001). Novelty seeking, reward dependence, and persistence were negatively correlated with apathy (r_s = [–0.274, –0.375], p < 0.001). Classification of patients according to personality and PD symptoms revealed 3 distinct clusters: i) neuropsychiatric phenotype (with high harm avoidance and low novelty seeking, hypodopaminergic neuropsychiatric symptoms and higher impulsivity), ii) motor phenotype (with low novelty seeking and higher motor severity), iii) benign phenotype (with low harm avoidance and high novelty seeking, reward dependence, and persistence traits clustered with lower symptoms severity and low impulsivity).

Conclusion:

Personality in early PD patients allows us to recognize 3 patients’ phenotypes. Identification of such subgroups may help to better understand their natural history. Their longitudinal follow-up will allow confirming whether some personality features might influence disease evolution and treatment.

Keywords

Neuropsychiatric symptoms non-motor symptoms Parkinson’s disease personality

INTRODUCTION

Parkinson’s disease (PD) is a heterogeneous neurodegenerative disorder with a wider variability of motor and non-motor manifestations than previously thought [1 –3]. Neuropsychiatric symptoms are common non-motor symptoms [4], including apathy, anxiety, and depression, and impulse control disorders as opposite ends of a hypo- and hyperdopaminergic behavioral spectrum [5]. Hypodopaminergic symptoms are related to the degeneration of ascending monoaminergic neurotransmitter systems, while the hyperdopaminergic symptoms are attributed to pulsatile dopaminergic stimulation and sensitization induced by antiparkinsonian drugs [5].

Since the beginning of the 20th century, several studies had described a parkinsonian personality, typically characterized as rigid, introverted, overcontrolled, cautious, conservative, punctual, serious, stoic, quiet, and industrious [6 –12]. Most previous studies have assessed personality based on Cloninger’s biosocial model [6 –11]. According to this model, personality is dependent on two main traits: temperaments and characters [13]. Temperaments (novelty seeking, harm avoidance, reward dependence, and persistence) are intended to be relatively stable personality dimensions related to genetics and neurotransmitters [13]. Individuals with high novelty seeking personality are often impulsive, extravagant, and irritable; those with high harm avoidance are pessimistic, fearful, shy, and fatigable; individuals with high reward dependence are sentimental, open, warm, and appreciative; and those with high persistence are often industrious, determined, ambitious, and perfectionistic [13]. Modulation of the four dimensions has been hypothesized to be related to dopamine, serotonin, noradrenaline, and glutamate, respectively [13].

PD patients were found to have less novelty seeking and more harm avoidance than control populations [6 –11]. Applying another model of personality, the five-factor model, PD patients showed a higher level of neuroticism and lower levels of openness and extraversion [6 , 12].

However, most studies have small sample sizes with heterogeneous disease duration and included mainly patients under dopaminergic medication [6–8 , 10–12]. Thus, these studies do not reflect well the personality at the early stages of the disease. The possibility of studying patients with untreated PD allows us to rule out the potential confounding effect of dopaminergic treatment on neuropsychiatric symptoms. Likewise, little is known about the relationship between clinical and neuropsychiatric symptoms and personality traits in PD patients.

We intend to investigate personality in de novo PD patients and explore its relationship with neuropsychiatric and motor symptoms.

METHODS

Participants

Patients were recruited from a multicenter, observational study on non-motor neuropsychiatric symptoms in de novo PD patients (NCT02786667). Inclusion criteria were: recent diagnosis of PD (< 2 years), no L-Dopa or Dopamine agonists treatment (only patients receiving rasagiline were allowed), and no cognitive impairment (defined as MATTIS Dementia rating scale score > 130/144). All patients gave their informed written consent.

Assessment

Demographic data (age and sex), age at PD onset, disease duration, first motor sign (akinetic-rigid versus tremor), and side of symptoms onset (right versus left) were collected.

Personality traits were assessed using the Temperament and Character Inventory-Revised (TCI-R) questionnaire [14]. It has 240 questions rated from one (definitively false) to five (definitively true) and measures the four dimensions of temperament, based on Cloninger’s biosocial model. Each dimension is divided into 4 sub-dimensions. The final score in percentage ranges from zero to 100%. The higher is the score, the higher the patient presents the associated personality dimension, with 50% being the midpoint of the ranging spectrum. Personality is defined by the interaction of these four dimensions and combinations of extremes (high or low) dimensions correspond to personality disorders.

Patients were assessed with a detailed neurological and neuropsychological assessment including: the MDS-UPDRS [15] for motor and non-motor symptoms severity (MDS-UPDRS-I for Non-Motor Aspects of Experiences of Daily Living, range 0 to 52, MDS-UPDRS-IB for Part IB covering the non-behavioral non-motor symptoms such as sleep, pain, urinary and constipation problems, light-headedness and fatigue, range 0 to 28, MDS-UPDRS-II for Motor Aspects of Experiences of Daily Living, range 0 to 52, and MDS-UPDRS-III for motor examination, range 0 to 132), the Starkstein apathy scale [16] for apathy (range 0 to 42), the Beck depression inventory-2 (BDI-2) [17] for depression (range 0 to 63), the State-Trait Anxiety Inventory for anxiety trait (STAI-trait) and state (STAI-state) [18], each range 20 to 80, the Ardouin Scale of Behavior in Parkinson’s Disease (ASBPD) [19] for apathy, anxiety, depression (each item range from 0 to 4 : 4 = severe disorder; 3 = marked disorder; 2 = moderate disorder; 1 = mild disorder; 0 = absence of disorder) and hyperdopaminergic behaviors (calculated as the sum of single items (each range from 0 to 4) of hyperdopaminergic behaviors, e.g., hypomania, and impulse control disorders, range 0 to 52), the Impulsive Behavior Scale [20] (UPPS, range 0 to 180), the MATTIS Dementia rating scale [21] (range 0 to 144) and the Frontal Assessment Battery [22] (FAB, range 0 to 18) for cognition and the Neuropathic Pain Symptom Inventory [23] (NPSI, range 0 to 100) for pain assessment. Quality of life was evaluated by PDQ-39 [24] (the summary index (PDQ-39 SI) was calculated by the sum of dimension total scores divided by 8).

We defined the motor subtype by calculating a “tremor score” and a “non-tremor score” for each patient according to Lewis et al. [25]. The tremor score derived from the sum of MDS-UPDRS items 3.15 to 3.18 divided by 10. The non-tremor score derived from the sum of MDS-UPDRS items 3.1 to 3.3, 3.9, 3.10, and 3.12 to 3.14 divided by 12. The motor subtype was classified as tremor-dominant or akinetic-rigid type, when the tremor score was at least twice the non-tremor score or the inverse, respectively. The remaining patients were classified as mixed type.

Statistical analysis

All data analyses were performed using the JASP Statistics software. Descriptive data are expressed as mean (standard deviation) for continuous variables and as absolute numbers (percentage) for categorical variables. The normality of continuous variables was assessed with the Shapiro–Wilk test. Variables that failed the Shapiro-Wilk test were analyzed with nonparametric statistics. Correlational analyses between each personality dimension and scores on the motor and non-motor scales were carried out through a bivariate Pearson’s correlation analysis (r) if normality were verified; otherwise, a Spearman’s rank correlation analysis (r_s). Secondly, to explore how different personality profiles and clinical variables clustered in early PD patients, we performed cluster analyses. A non-hierarchical (K-means) clustering analysis with z-score standardization was performed using as variables personality dimensions, motor- and non-motor data. MDS-UPDRS-IB, MDS-UPDRS-II, MDS-UPDRS-III, ASBPD score for depression, anxiety, and apathy, UPSS, and NPSI were introduced in the clustering analysis together with the four TCI-R dimensions. To avoid redundancies, we decided to exclude BDI-2, STAI, and Starkstein apathy scale given the high correlation coefficient between these scores and ASBPD depression, anxiety, and apathy scores (r_s > 0.500). Since the small number of patients with an elevated hyperdopaminergic ASBPD score (9/193), this score was also not included in the clustering analysis, considering it would not contribute significantly to the differentiation of clusters. Determination of the optimal number of clusters was based on the Calinski-Harabasz pseudo-F value and Silhouette Score in successive steps of division in two, three, or four clusters. Then, for each variable included in cluster analysis as well as other clinical and demographic variables (age, sex, quality of life) we used parametric (one-way ANOVAs with Bonferroni post-hoc analysis) or nonparametric statistics (Kruskal–Wallis test with pairwise post hoc analysis), as appropriate, to compare means between the identified clusters. A chi-square test or Fisher’s exact test was used for the comparison of categorical data. No imputation was made for missing data. Subjects with missing values were not included in the analysis (2.5% of the initial cohort of 198 patients). A p-value of≤0.05 was considered significant. After Bonferroni adjustment to correct for multiple testing, a p-value of < 0.001 was considered significant.

RESULTS

Of 198 de novo PD patients included in the study, full data were available for 193 patients for the analysis: 119 men (62%), mean age of 58.4 (8.8) years, mean age at PD onset 56.8 (9.1) years, 97 (50%) with an akinetic-rigid motor onset, mean OFF MDS-UPDRS-III 24.9 (9.7). None of the subjects had received levodopa or dopamine agonist medication but fifty (26%) were taking rasagiline. Table 1 shows the clinical characteristics of the studied group.

Table 1

Demographic, motor, personality, and neuropsychological characteristics (n = 193 patients)

Demographics
Male (male/female)	119/74
Age, y	58.4 (8.8)
Clinical characteristics
Age at PD onset, y	56.8 (9.1)
Disease duration, y	1.9 (1.8)
MDS-UPDRS I	7.4 (4.9)
MDS-UPDRS IB	4.6 (2.9)
MDS-UPDRS II	7.6 (4.7)
MDS-UPDRS III	24.9 (9.7)
Side of onset (right/left/bilateral)	101/86/6
First motor symptom (akinetic-rigid/tremor/mixed)	97/87/9
Motor subtype (akinetic-rigid/tremor/mixed)	113/9/71
Personality (TCI-R)
Novelty seeking (NS)	42.6 (8.4)
Exploratory excitability NS1	47.9 (12.1)
Impulsiveness NS2	40.9 (13.4)
Extravagance NS3	42.1 (14.9)
Disorderliness NS4	37.2 (12.0)
Harm avoidance (HA)	50.0 (13.4)
Anticipatory worry HA1	47.0 (14.4)
Fear of uncertainty HA2	62.0 (18.3)
Shyness HA3	45.3 (18.7)
Fatigability HA4	47.3 (17.6)
Reward dependence (RD)	58.9 (11.0)
Sentimentality (RD1)	64.1 (11.5)
Openness to warm communication (RD2)	60.3 (13.4)
Attachment (RD3)	52.8 (19.2)
Dependence (RD4)	56.8 (14.2)
Persistence (P)	59.4 (13.1)
Eagerness of effort (P1)	58.7 (15.3)
Work hardened (P2)	61.8 (14.6)
Ambitious (P3)	56.5 (15.2)
Perfectionist (P4)	61.0 (14.8)
Non-motor status
Depression (BDI-2)	10.0 (7.6)
Anxiety (STAI-state)	35.0 (10.0)
Anxiety (STAI-trait)	40.7 (10.5)
Apathy (Starkstein apathy scale)	11.7 (6.0)
Depression (Ardouin)	0.7 (0.9)
Anxiety (Ardouin)	0.9 (1.0)
Apathy (Ardouin)	0.8 (1.0)
Hypodopaminergic behaviors (Ardouin)	3.3 (3.0)
Hyperdopaminergic behaviors (Ardouin)	0.6 (1.1)
Impulsive Behavior (UPSS)	88.9 (13.4)
MATTIS scale score	139.3 (3.4)
FAB	16.7 (1.0)
Neuropathic Pain (NPSI)	7.0 (10.3)
PDQ-39 SI	20.6 (13.4)

Values are mean (SD) or n.

Personality assessment (Table 1 and Supplementary Figure 1) revealed: a higher level of fear of uncertainty (62%), low mean novelty seeking (43%), and high mean reward dependence and persistence (59% and 59%, respectively). While only 31 patients had a novelty seeking score superior to 50%, 90, 161, and 147 patients had a harm avoidance, reward dependence, and persistence score superior to 50%, respectively. Figure 1 shows the descriptive data of personality assessment of our cohort and data from the French and Belgian normative population with 78 healthy French subjects (mean age (32.5±13.3)) [14] and 958 French-speaking participants of Belgium (546 women with a mean age of 33.6 (15.1) years) and 412 men with a mean age of 36.2 (14.9) years) [26]. Our PD patients showed low novelty seeking (42.6% vs. 48.4% and 46.6%), high harm avoidance (50.0% vs. 44.2% and 46.2%), and similar reward dependence (58.9% vs. 59.6% and 59.7%) and persistence (59.4% vs. 60.4% and 59.1%) than the French and Belgian normative population, respectively (no inferential statistics analysis was performed).

Fig. 1

Personality traits of PD patients and healthy controls using TCI-R. Novelty seeking, harm avoidance, reward dependence, and persistence mean score (and SD) of de novo PD patients compared with results from validation studies of the TCI-R with healthy controls in French [14] and Belgian populations [26]. Our PD patients showed low novelty seeking (42.6% (8.4)) vs. 48.4% (10.9) and 46.6% (10.1)), high harm avoidance (50.0% (13.4)) vs. 44.2% (12.3) and 46.2% (13.8)), and similar reward dependence (58.9% (11.0)) vs. 59.6% (12.4) and 59.7% (11.2)) and persistence (59.4% (13.1)) vs. 60.4% (12.2) and 59.1% (13.2)) than the French and Belgian normative population, respectively (no inferential statistics analysis was performed).

At the time of evaluation forty-eight patients (25%) were significantly apathetic, 34 patients (18%) were significantly depressive and 50 patients (26%) were significantly anxious (ASBPD score≥2). Twenty patients had a past diagnosis of anxiety and fifty-four of depression (only 15 of them were still with depressive symptoms at the study evaluation). Only nine patients (4.7%) showed hyperdopaminergic behaviors (ASBPD score≥2 on one of the items of hyperdopaminergic behaviors). Of these nine patients, five had eating behavior, one creativity, one hobbyism, one risk-taking behavior, and one compulsive shopping.

Correlation analysis results are shown in Table 2. Harm avoidance was significantly positively correlated with the severity of depression, anxiety, and apathy (r_s between 0.435 and 0.676) and with the MDS-UPDRS part I, IB, and II (r_s between 0.349 and 0.508) and negatively correlated with quality of life (r_s = –0.492). Additionally, a weak positive correlation was found between harm avoidance and women (r_s = 0.257). Novelty seeking, reward dependence, and persistence were negatively correlated with apathy (r_s between –0.274 and –0.375). A significant positive correlation was found between novelty seeking and UPSS (r_s = 0.239).

Table 2

Correlations between TCI-R dimensions and clinical features of PD patients

		NS	HA	RD	P
Women	Spearman’s r_s	0.181	0.257	0.190	–0.110
	p-value	0.011	< 0.001	0.008	0.124
Age	Spearman’s r_s	–0.182	0.103	–0.198	–0.161
	p-value	0.011	0.150	0.005	0.024
Right hemibody onset	Spearman’s r_s	0.069	–0.052	0.045	–0.090
	p-value	0.524	0.469	0.988	0.100
MDS-UPDRS I	Spearman’s r_s	–0.185	0.508	–0.057	–0.161
	p-value	0.009	< 0.001	0.425	0.025
MDS-UPDRS IB	Spearman’s r_s	–0.135	0.372	0.025	–0.088
	p-value	0.058	< 0.001	0.729	0.221
MDS-UPDRS II	Spearman’s r_s	–0.180	0.349	–0.132	–0.176
	p-value	0.012	< 0.001	0.066	0.013
MDS-UPDRS III	Spearman’s r_s	–0.162	0.144	–0.126	–0.059
	p-value	0.023	0.043	0.079	0.413
Depression (BDI-2)	Spearman’s r_s	–0.145	0.628	–0.068	–0.208
	p-value	0.043	< 0.001	0.344	0.003
Anxiety (STAI-state)	Spearman’s r_s	–0.086	0.508	–0.106	–0.163
	p-value	0.229	< 0.001	0.140	0.022
Anxiety (STAI-trait)	Spearman’s r_s	–0.079	0.676	–0.077	–0.303
	p-value	0.272	< 0.001	0.283	< 0.001
Apathy (Starkstein)	Spearman’s r_s	–0.274	0.536	–0.267	–0.375
	p-value	< 0.001	< 0.001	< 0.001	< 0.001
Depression (Ardouin)	Spearman’s r_s	–0.190	0.478	–0.142	–0.192
	p-value	0.008	< 0.001	0.047	0.007
Anxiety (Ardouin)	Spearman’s r_s	–0.154	0.435	–0.065	–0.096
	p-value	0.032	< 0.001	0.367	0.183
Apathy (Ardouin)	Spearman’s r_s	–0.221	0.495	–0.188	–0.256
	p-value	0.002	< 0.001	0.008	< 0.001
Hyperdopaminergic behaviors (Ardouin)	Spearman’s r_s	0.064	0.041	0.062	–0.055
	p-value	0.375	0.568	0.387	0.446
Impulsive Behavior (UPSS)	Spearman’s r_s	0.239	0.112	–0.010	–0.137
	p-value	< 0.001	0.119	0.887	0.056
MATTIS scale score	Spearman’s r_s	0.182	–0.080	0.168	–0.057
	p-value	0.009	0.435	0.008	0.252
FAB	Spearman’s r_s	0.063	–0.112	0.071	–0.125
	p-value	0.382	0.118	0.326	0.080
Neuropathic Pain (NPSI)	Spearman’s r_s	0.028	0.205	0.066	0.016
	p-value	0.699	0.004	0.359	0.826
PDQ-39	Spearman’s r_s	–0.072	0.492	–0.181	–0.136
	p-value	0.318	< 0.001	0.011	0.057

NS, novelty seeking; HA, harm avoidance; RD, reward dependence; P, persistence. Spearman’s rank correlation analysis (r_s-values). Following Bonferroni correction for 80 multiple tests, p < 0.001 was considered a significant.

Clustering analysis divided our PD patients into three main clusters (Fig. 2 and Table 3). The clustering optimum was attained for the 3 clusters solution (Calinski-Harabasz pseudo-F = 37.165 and Silhouette score = 0.180). Cluster 1 included 51 patients with higher harm avoidance (63%) and lower novelty seeking (41%), cluster 2 included 34 patients with low novelty seeking (37%) but a median level of harm avoidance (53%), and cluster 3 included 108 patients with a lower harm avoidance (43%) and higher novelty seeking (45%), reward dependence (62%), and persistence (64%). Cluster 1 showed a higher severity of depression, anxiety, apathy, and impulsivity (ASBPD and UPSS) and an intermediate severity of motor symptoms (MDS-UPDRS-II and MDS-UPDRS-III). Cluster 2 had a higher severity in motor symptoms (MDS-UPDRS-II and MDS-UPDRS-III), with a higher severity in non-tremor items of MDS-UPDRS-III. Cluster 3 showed a lower severity of both motor and non-motor symptoms. Both clusters 1 and 2 had a higher MDS-UPDRS-IB score, covering other non-motor symptoms such as sleep, urinary, and constipation problems (p < 0.001) and a higher NPSI score (p < 0.004) than cluster 3. Quality of life (PDQ-39 SI) was worse in clusters 1 and 2 (p < 0.001), with worse scores in patients of cluster 1. Sex, PD motor subtype, and the side of symptoms onset were not significantly different between clusters. Past diagnoses of depression and anxiety did not differ between clusters (p = 0.225 and p = 0.167). There was no difference in the number of patients receiving rasagiline (p = 0.944).

Fig. 2

Clustering analysis of personality traits, motor- and non-motor symptoms. K-means clustering analysis included z-scores of 12 factors: personality dimensions (novelty seeking, harm avoidance, reward dependence and persistence), MDS-UPDRS part IB (non-behavioral non-motor symptoms), II and III, Ardouin score (ASBPD) for depression, anxiety and apathy, Impulsive Behavior Scale (UPPS) and Neuropathic Pain Symptom Inventory (NPSI). Since factors have different scales, cluster means for each factor are displayed as standardized scores relative to each overall mean. Three distinct clusters were found: cluster 1 (51 patients) with high harm avoidance, low novelty seeking, hypodopaminergic neuropsychiatric symptoms and an intermediate motor score severity; cluster 2 (34 patients) with low novelty seeking, and higher motor severity; and cluster 3 (108 patients) with low harm avoidance and high novelty seeking, reward dependence and persistence with lower symptoms severity.

Table 3

Demographic and clinical features of early PD patients in the three clusters

	Cluster 1(n = 51)	Cluster 2(n = 34)	Cluster 3(n = 108)	p	1 vs. 2	1 vs. 3	2 vs. 3
Male (male)	27 (53)	23 (68)	69 (64)	0.304^a
Age	60.4 (7.3)	62.0 (7.7)	57.0 (9.4)	0.005^c	0.138	0.019	0.001
Side of onset (right)	22 (43)	21 (62)	58 (54)	0.215^a
Motor subtype (akinetic-rigid)	35 (69)	17 (50)	61 (56)	0.157^b
Personality (TCI-R)
Novelty seeking (NS)	40.8 (8.6)	37.0 (8.8)	45.2 (7.1)	< 0.001 ^c	0.037	< 0.001	< 0.001
Harm avoidance (HA)	62.7 (9.2)	52.7 (10.9)	43.1 (10.9)	< 0.001 ^d	< 0.001	< 0.001	< 0.001
Reward dependence (RD)	57.0 (9.4)	53.1 (8.8)	61.6 (11.5)	< 0.001 ^c	0.043	0.001	< 0.001
Persistence (P)	51.5 (12.7)	56.9 (13.8)	63.9 (11.1)	< 0.001 ^c	0.050	< 0.001	0.0004
Motor and Non-motor status
MDS-UPDRS I	11.7 (4.9)	8.9 (4.3)	4.9 (3.3)	< 0.001 ^c	0.018	< 0.001	< 0.001
MDS-UPDRS IB	6.3 (2.8)	6.3 (2.8)	3.3 (2.3)	< 0.001 ^c	0.457	< 0.001	< 0.001
MDS-UPDRS II	9.0 (4.4)	12.8 (4.6)	5.3 (3.1)	< 0.001 ^c	0.001	< 0.001	< 0.001
MDS-UPDRS III	25.4 (8.6)	35.3 (9.6)	21.3 (7.6)	< 0.001 ^d	< 0.001	0.008	< 0.001
Tremor UPDRS III	2.8 (3.0)	4.8 (3.3)	2.9 (3.0)	0.005^c	0.005	0.472	0.003
Non-tremor UPDRS III	9.9 (4.0)	13.7 (3.8)	8.2 (3.7)	< 0.001 ^d	< 0.001	0.009	< 0.001
Depression (Ardouin)	1.7 (0.9)	0.3 (0.5)	0.5 (0.6)	< 0.001 ^c	< 0.001	< 0.001	0.019
Anxiety (Ardouin)	2.0 (0.8)	0.3 (0.5)	0.5 (0.6)	< 0.001 ^c	< 0.001	< 0.001	0.152
Apathy (Ardouin)	1.9 (1.0)	0.7 (0.9)	0.3 (0.5)	< 0.001 ^c	< 0.001	< 0.001	0.006
Hyperdopa (Ardouin)	0.8 (1.3)	0.6 (0.9)	0.6 (1.1)	0.682^c
Impulsive Behavior (UPSS)	93.9 (11.6)	85.2 (12.4)	87.9 (13.7)	0.005^d	0.008	0.023	0.837
Neuropathic Pain (NPSI)	11.5 (13.5)	10.1 (11.9)	3.8 (6.1)	< 0.001 ^c	0.321	< 0.001	0.002
PDQ-39 SI	31.5 (12.3)	23.3 (9.9)	14.6 (8.9)	< 0.001 ^c	0.008	< 0.001	< 0.001

MDS-UPDRS, MDS-sponsored Revision of the Unified Parkinson’s Disease Rating Scale; MDS-UPDRS-I, UPDRS part I, Non-Motor Aspects of Experiences of Daily Living; MDS-UPDRS-IB, UPDRS part I B, covering the non-behavioral non-motor symptoms such as sleep, pain, urinary and constipation problems, light-headedness and fatigue; UPDRS-II, UPDRS part II, Activities of Daily Living; UPDRS-III, UPDRS part III, Motor Examination; Ardouin Scale of Behavior in Parkinson’s Disease for depression, anxiety and apathy; UPPS, Urgency, Premeditation, Perseverance, Sensation Seeking, Impulsive Behavior Scale; NPSI, Neuropathic Pain Symptom Inventory. Tremor UPDRS III = sum of MDS-UPDRS items 3.15 to 3.18, non-tremor UPDRS III = sum of MDS-UPDRS items 3.1 to 3.3, 3.9, 3.10, and 3.12 to 3.14. Values are mean (SD) or n (%). ^aPearsons χ² test; ^bFishers exact test; ^cKruskal-Wallis test with Dunn’s post hoc test; ^dANOVA test with Bonferroni post-hoc analysis. Following Bonferroni correction, p < 0.001 was considered a significant.

TCI-R sub-dimensions were subsequently analyzed. Novelty seeking was significantly higher in cluster 3 compared with other clusters as did 2 of its 4 sub-dimensions: exploratory excitability (3 vs. 1, and 2, p < 0.001), and extravagance (3 vs. 2, p < 0.001). Harm avoidance was significantly different between the 3 clusters as did 4 of its 4 sub-dimensions. Anticipatory worry and fatigability differed significantly between the 3 clusters (p < 0.009 and p < 0.001) while fear of uncertainty and shyness were significantly different between clusters 1 and 3 (p < 0.001). Reward dependence was significantly higher in cluster 3 as did 2 of its 4 sub-dimensions: openness to warm communication (p < 0.006), and attachment (p < 0.001). Persistence was significantly higher in cluster 3 as did 4 of its 4 sub-dimensions compared to cluster 1: eagerness of effort, work-hardened, ambitious, and perfectionist (p < 0.001).

DISCUSSION

This is the first study on personality in de novo PD patients and its relationship with motor and non-motor clinical correlates. Using Cloninger’s biosocial model, we assessed the personality of 193 de novo PD patients. Our patients showed low novelty seeking (43%), high harm avoidance (50%), and similar reward dependence and persistence scores (59%) than healthy populations [14, 26] (Fig. 1). Most studies of personality in PD applied previous versions of the TCI-R questionnaire, namely TPQ and TCI tools, also derived from Cloninger’s model [13] and composed of true/false items: like us, they have shown a reduced novelty seeking and increased harm avoidance in PD patients in comparison to healthy controls [6 –11]. Most of these studies have been based on small PD samples with heterogeneous disease duration, and fewer studies focused on the investigation of personality traits of early untreated PD patients [9, 12]. A study of 61 untreated PD patients (< 5 years of disease duration) showed slightly lower novelty seeking and higher harm avoidance [9]. Another study of 941 early PD patients (< 3.5 years from diagnosis) but under treatment, reported that patients were more neurotic, less extraverted, and less open than controls [12]. Traditionally, PD patients have been described with “typical personality traits” (rigid, introverted, overcontrolled, cautious, conservative) that precede the clinical motor onset of PD and that remain distinct from healthy controls with disease progression [6 –12]. Some population-based cohort studies also studied the association between these personality traits and the risk of developing PD with contradictory results [27, 28].

Since previous studies of personality traits in PD patients are not entirely consistent, we speculated if, in fact, more than a particular parkinsonian personality, there are different personality traits that play a role in the presence of different clinical phenotypes.

Classification of patients according to personality traits, motor, and non-motor symptoms revealed the presence of 3 distinct subtypes of patients: i) group 1, with 26% of patients, had high harm avoidance and low novelty seeking traits and hypodopaminergic neuropsychiatric symptoms, impulsivity, and intermediate motor severity (= neuropsychiatric phenotype); ii) group 2, with 18% of patients, had a low novelty seeking trait and a higher motor severity, without neuropsychiatric symptoms but with similar severity of other non-motor symptoms as group 1 (= motor phenotype); iii) group 3, with 56% of patients, presented with lower harm avoidance, higher novelty seeking, reward dependence and persistence traits and lower motor severity and lower prevalence of non-motor symptoms (= benign phenotype). The 3 phenotypes did not differ in age, gender, or motor subtype. Although the motor subtype did not differ between the 3 phenotypes, the higher motor severity of the motor phenotype (group 2) was driven by a higher severity in non-tremor items of MDS-UPDRS-III, more than the tremor items score. While the neuropsychiatric phenotype (1) and motor phenotype (2) had a higher harm avoidance, characterized by excessive worrying, pessimism, shyness, doubtfulness, and easily fatigued, the benign phenotype (3) had a low harm avoidance, characterized by optimism, extrovert, confidence, and energy. Patients with the benign phenotype (high novelty seeking, reward dependence, and persistence) present with higher exploratory excitability and extravagance, openness to warm communication and attachment, and eagerness of effort and work-hardened.

Over the last decade, research has focused on non-motor symptoms and heterogeneity in PD [2–4 , 30]. Disease manifestations and rates of progression vary greatly, and these differences are present since the disease onset [1–4 , 30]. Increasing attempts are made to define different subtypes of PD patients, based on their baseline motor and non-motor characteristics, with different long-term prognoses [1–4 , 29–32]. Non-motor symptoms have a key role in differentiating PD phenotypes: mood and apathy were associated with more severe motor symptoms [31] and RBD has been associated with poor prognosis [32]. More recently four different clusters of PD presentation were reported: 1) fast motor progression with symmetrical motor signs, poor olfaction, cognition, and postural hypotension; 2) mild motor and non-motor disease with intermediate progression rate; 3) severe motor disease, poor psychological well-being and poor sleep with intermediate motor progression; 4) slow motor progression, unilateral presentation, tremor-dominant [30]. However, none of these studies included personality in the classification of PD patients. Personality, as a constitutive characteristic of the subject, might help explain heterogeneity in PD. The follow-up of our cohort will help to understand whether our classification can help differentiate patient evolution and treatment response.

Cloninger’s defined novelty seeking as an individual’s tendency to action and exploratory behaviors, harm avoidance as a tendency to inhibit behaviors to avoid punishment, non-reward, and novelty, reward dependence as a tendency towards the maintenance of ongoing behaviors previously associated with reward and non-punishment and persistence as the ability to generate and maintain arousal and motivation internally, in the absence of immediate external reward [13]. Cloninger’s proposed a relationship between personality and monoaminergic neurotransmitter systems, linking the dopaminergic system to exploratory behaviors and response to novel stimuli (novelty seeking); serotoninergic system to inhibitory behaviors (harm avoidance); noradrenergic system to response to rewards and better maintenance (reward dependence) [13]. In PD patients, it has been claimed that the lower scores in novelty seeking are related to the dopaminergic deficit. The increased novelty seeking score after the introduction of dopamine agonist treatment shown in Bódi et al. [33] and higher novelty seeking scores in candidates for DBS treatment or advanced PD population [11] compared to controls and early untreated [9] PD patients reinforce this hypothesis. Later studies have shown that the association between different traits according to the Cloninger model and neurotransmitters is much less clear than originally stated [9, 34].

Cloninger’s model postulates harm avoidance and novelty seeking are also the most directly involved in susceptibility to mood disorders [26]. In our study, we found a prevalence of apathy, depression, and anxiety of 25%, 18%, and 26%, respectively, consistent with previous studies [4, 31]. These symptoms are commonly associated with each other. The dysfunction of the mesolimbic dopaminergic limbic circuit and mesolimbic serotonergic and noradrenergic circuits are implied in their pathophysiology [35]. In early-stage PD, serotonergic dysfunction has been shown to play a prominent role in the pathophysiology of apathy and mood symptoms [35]. Our results showed an association between personality and mood disorders. Harm avoidance was strongly positively correlated with the severity of depression, anxiety, and apathy in PD. Novelty seeking, reward dependence, and persistence were weakly negatively correlated with apathy, but not with depression or anxiety. Other smaller studies focusing on PD also revealed a strong association between high harm avoidance or increased neuroticism with depression and anxiety [36, 37]. Studies focusing on personality and apathy in PD are scarce [38]. Applying the TPQ, Pluck and Brown did not find significant differences in personality measures with high and low apathy scores [38]. The causal link between mood disorders and harm avoidance can be argued. Cloninger’s defended that personality dimensions are relatively stable through life and related to genetics and neurotransmitters. So, patients with higher harm avoidance can have a chronic maladaptive strategy that made them more susceptible to depression or anxiety. On the other hand, it is also possible that mood disorders lead to changes in personality and the co-occurrence of depression and anxiety and high harm avoidance scores may be a reflection of the intertwined nature of traits and states. Lhommée et al have previously demonstrated significant personality changes in PD patients after deep brain stimulation and a major reduction in antiparkinsonian treatment [10]. Harm avoidance increased, and extravagance (subdimension of novelty seeking) and persistence decreased after surgery, possibly related to the change from a preoperative hyperdopaminergic to a postoperative hypodopaminergic state [10].

Interestingly, the neuropsychiatric phenotype showed higher impulsivity scores, which is counterintuitive. The apathetic patient is not ready to make an effort, nor ready to wait for a reward and will need it right away, with a tendency to think and act rashly, which can be interpreted as “impulsive”. The distinct psychological process of dopamine-related motivation systems of ‘wanting’ a reward from the hedonically ‘liking’ the same reward could explain this paradox [39]. A disruption of goal-directed decision-making is proposed as another possible mechanism in a recent study showing that apathy and impulsivity correlated positively [40]. Hypodopaminergic behavioral symptoms and impulsivity might be predisposing factors for the development and severity of impulse control disorders, possibly induced by the dopaminergic sensitization in the mesolimbic circuit and probably related to a higher extent of the dopaminergic depletion in the ventral striatum [5]. The longitudinal follow-up of these patients will allow confirming whether some personality traits represent a risk factor to develop impulse control disorders.

Hyperdopaminergic ASBPD score was not included in the cluster analysis, which some could argue could be one important phenotype. The decision was taken, given the small number of patients with an elevated hyperdopaminergic score (9/193). In new set of cluster analysis with the hyperdopaminergic score, we found a lower statistical significance level of the different clusters (lower silhouette score and Calinski-Harabasz pseudo-F value and the hyperdopaminergic score was not significantly different between clusters). Impulse control disorders are a drug-induced complication and thus usually rare in untreated PD patients [5, 31], so it is not surprising that only 5% of our PD patients manifested moderate impulse control disorders. Additionally, compulsive eating was the most frequent symptom, which can also be related to depressed and anxious feelings (3 of the 5 patients were significantly depressive or anxious at the time of evaluation (ASBPD score≥2)).

Finally, harm avoidance was also negatively correlated with quality of life and neuropsychiatric phenotype showed the worse quality of life. Non-motor symptoms, in particular mood and apathy, represent a major determinant of quality of life in PD patients. Although personality traits were shown to contribute to many chronic diseases’ quality of life, fewer studies investigated it in PD [40]. High neuroticism was associated with worse quality of life in PD [41] but no studies applied Cloninger’s model.

Although it would be interesting to investigate the association between personality traits and cognition in PD patients, we did not include cognition in the model since one of the study inclusion criteria was a normal MATTIS Dementia rating scale score.

We acknowledge that our study has some limitations. First, our cohort is likely not representative of the whole PD population (relatively young, probably because of the recruitment in a tertiary care center). Secondly, the relatively small sample size and the lack of a control group may have limited our results and power of statistical analysis. Lastly, as in every study including early PD, we cannot exclude that a minority of patients may have atypical parkinsonism, mimicking PD.

In conclusion, our correlation and cluster analysis showed a strong relationship between personality, motor, and neuropsychiatric symptoms, allowing us to recognize 3 patients’ phenotypes (predominant neuropsychiatric, predominant motor, and benign). More than a unique parkinsonian personality, different traits might help explain heterogeneity in PD. Although, the association between different traits according to the Cloninger model and neurotransmitters is much less clear than originally stated, and the lack of strong biological data in support of this statement, we found that clinically personality, neurotransmitters imbalance, and neuropsychiatric symptoms seem to cluster in a way that may be of clinical value. Clinical recognition and characterization of these groups will allow a better understanding of the natural history of specific subtypes and better tailoring of treatment strategies. Their longitudinal follow-up will allow confirming whether some personality features might influence disease evolution and treatment. Combining clinical subtyping with imaging, and biological markers might help to optimize the definition of different subgroups with different evolution and response to treatment.

Footnotes

ACKNOWLEDGMENTS

We thank Chantal Delon-Martin (researcher from the Inserm, U1216, CHU Grenoble Alpes, Grenoble Institute Neurosciences) for the help in the statistical analysis.

The study was an Investigator-Initiated Study, where UCB provided financial support. The sponsor had no role in the study design, data analysis and interpretation, and in writing the manuscript.

CONFLICT OF INTEREST

B.M., E.L., A.B., H.K., E.S., P.P., V.F., S.M., F.D. declare that they have not received any sort of funding for the last 12 months. M.A. declares honoraria from Orkyn and Aguettant in the last 12 months. C.T. declares honoraria from Kyowa Kirin. JL.H. declares honoraria from advisory board de UCB, Abbvie, Medtronic. J.P.A. has served on advisory boards for Teva, UCB Pharma, AbbVie, and Zambon. He has received honoraria for presenting lectures from AbbVie, Medtronics, Novartis, Zambon, and UCB. E.M. has received honoraria from Abbott, Medtronic and Kyowa. S.T. declares honorarium from Orion, Boston. Grants from Neurodis, France Parkinson. P.K. declares grants from Swiss National Science Foundation, ROGER DE SPOELBERCH Foundation, Bertarelli Foundation, Annemarie Opprecht Foundation, Parkinson Schweiz, Michael J Fox Foundation, Aleva Neurotherapeutics, and Boston Scientific, personal fees (lecturing fees to employing institution/travel expenses to scientific meetings) from Boston Scientific, Bial, and Zambon outside the submitted work. A.C. declares research grants from France Parkinson Association and Medtronic, and lecturing fees from ABBVIE.

The supplementary material is available in the electronic version of this article: .

References

Nutt

(2016) Motor subtype in Parkinson’s disease: Different disorders or different stages of disease? Mov Disord 31, 957–961.

Erro

, Vitale

, Amboni

, Picillo

, Moccia

, Longo

, Santangelo

, De Rosa

, Allocca

, Giordano

, Orefice

, De Michele

, Santoro

, Pellecchia

, Barone

(2013) The heterogeneity of early Parkinson’s disease: A cluster analysis on newly diagnosed untreated patients. PLoS One 8, e70244.

Berg

, Borghammer

, Fereshtehnejad

, Heinzel

, Horsager

, Schaeffer

, Postuma

(2021) Prodromal Parkinson disease subtypes - key to understanding heterogeneity. Nat Rev Neurol 17, 349–361.

Weintraub

, Simuni

, Caspell-Garcia

, Coffey

, Lasch

, Siderowf

, Aarsland

, Barone

, Burn

, Chahine

, Eberling

, Espay

, Foster

, Leverenz

, Litvan

, Richard

, Troyer

, Hawkins KA; Parkinson’s Progression Markers Initiative (2015) Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson’s disease. Mov Disord 30, 919–927.

Castrioto

, Thobois

, Carnicella

, Maillet

, Krack

(2016) Emotional manifestations of PD: Neurobiological basis. Mov Disord 31, 1103–1113.

Poletti

, Bonuccelli

(2012) Personality traits in patients with Parkinson’s disease: Assessment and clinical implications. J Neurol 259, 1029–1038.

Santangelo

, Garramone

, Baiano

, D’Iorio

, Piscopo

, Raimo

, Vitale

(2018) Personality and Parkinson’s disease: A meta-analysis. Parkinsonism Relat Disord 49, 67–74.

Jacobs

, Heberlein

, Vieregge

(2001) . Personality traits in young patients with Parkinson’s disease. Acta Neurol Scand 103, 82–87.

Kaasinen

, Nurmi

, Bergman

, Eskola

, Solin

, Sonninen

, Rinne

(2001) Personality traits and brain dopaminergic function in Parkinson’s disease. Proc Natl Acad Sci U S A 98, 13272–13277.

10.

Lhommée

, Boyer

, Wack

, Pélissier

, Klinger

, Schmitt

, Bichon

, Fraix

, Chabardès

, Mertens

, Castrioto

, Kistner

, Broussolle

, Thobois

, Krack

(2017) Personality, dopamine, and Parkinson’s disease: Insights from subthalamic stimulation. Mov Disord 32, 1191–1200.

11.

Boussac

, Arbus

, Dupouy

, Harroch

, Rousseau

, Croiset

, Ory-Magne

, Rascol

, Moreau

, Rolland

, Maltête

, Rouaud

, Meyer

, Drapier

, Giordana

, Anheim

, Hainque

, Jarraya

, Benatru

, Auzou

, Belamri

, Tir

, Marques

, Thobois

, Eusebio

, Corvol

, Devos

, Brefel-Courbon

; PREDI-STIM study group (2021) Personality dimensions of patients can change during the course of parkinson’s disease. PLoS One 16, e0245142.

12.

Baig

, Lawton

, Rolinski

, Ruffmann

, Klein

, Nithi

, Okai

, Ben-Shlomo

, Hu

(2017) Personality and addictive behaviors in early Parkinson’s disease and REM sleep behavior disorder. Parkinsonism Relat Disord 37, 72–78.

13.

Cloninger

, Svrakic

(1997) Integrative psychobiological approach to psychiatric assessment and treatment. Psychiatry 60, 120–141.

14.

Pelissolo

, Mallet

, Baleyte

, Michel

, Cloninger

, Allilaire

, Jouvent

(2005) The Temperament and Character Inventory-Revised (TCI-R): Psychometric characteristics of the French version. Acta Psychiatr Scand 112, 126–133.

15.

Goetz

, Tilley

, Shaftman

, Stebbins

, Fahn

, Martinez-Martin

, Poewe

, Sampaio

, Stern

, Dodel

, Dubois

, Holloway

, Jankovic

, Kulisevsky

, Lang

, Lees

, Leurgans

, LeWitt

, Nyenhuis

, Olanow

, Rascol

, Schrag

, Teresi

, van Hilten

, LaPelle

;Movement Disorder Society UPDRS Revision Task Force (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 23, 2129–2170.

16.

Starkstein

, Mayberg

, Preziosi

, Andrezejewski

, Leiguarda

, Robinson

(1992) Reliability, validity, and clinical correlates of apathy in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 4, 134–139.

17.

Beck

, Steer

, Ball

, Ranieri

(1996) Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess 67, 588–597.

18.

Spielberger

, Gorsuch

, Lushene

, Vagg

(1983) Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo Alto.

19.

Ardouin

, Chéreau

, Llorca

, Lhommée

, Durif

, Pollak

, Krack

; groupe évaluation comportementale de la maladie de Parkinson (2009) Evaluation des troubles comportementaux hyper- et hypodopaminergiques dans la maladie de Parkinson [Assessment of hyper- and hypodopaminergic behaviors in Parkinson’s disease]. Rev Neurol (Paris) 165, 845–856.

20.

Van der Linden

, d’Acremont

, Zermatten

, Jermann

, Larøi

, Willems

, Juillerat

, Bechara

(2006) A French adaptation of the UPPS Impulsive Behavior Scale: Confirmatory factor analysis in a sample of undergraduate students. Eur J Psychol Assess 22, 38–42.

21.

Mattis

(1976) Mental status examination for organic mental syndrome in the elderly patient. In Geriatric Psychiatry, Bellack L, Karusu TB, eds. Grune & Stratton, New York, pp. 77–121.

22.

Dubois

, Slachevsky

, Litvan

, Pillon

(2000) The FAB: A Frontal Assessment Battery at bedside. Neurology 55, 1621–1626.

23.

Bouhassira

, Attal

, Fermanian

, Alchaar

, Gautron

, Masquelier

, Rostaing

, Lanteri-Minet

, Collin

, Grisart

, Boureau

(2004) Development and validation of the Neuropathic Pain Symptom Inventory.. Pain 108, 248–257.

24.

Jenkinson

, Fitzpatrick

, Peto

, Greenhall

, Hyman

(1997) The Parkinson’s Disease Questionnaire (PDQ-39): Development and validation of a Parkinson’s disease summary index score. Age Ageing 26, 353–357.

25.

Lewis

, Foltynie

, Blackwell

, Robbins

, Owen

, Barker

(2005) Heterogeneity of Parkinson’s disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 76, 343–348.

26.

Hansenne

, Delhez

, Cloninger

(2005) Psychometric properties of the temperament and character inventory-revised (TCI-R) in a Belgian sample. J Pers Assess 85, 40–49.

27.

Terracciano

, Aschwanden

, Stephan

, Cerasa

, Passamonti

, Toschi

, Sutin

(2021) Neuroticism and risk of Parkinson’s disease: A meta-analysis. Mov Disord 36, 1863–1870.

28.

Arabia

, Grossardt

, Colligan

, Bower

, Maraganore

, Ahlskog

, Geda

, Rocca

(2010) Novelty seeking and introversion do not predict the long-term risk of Parkinson disease. Neurology 75, 349–357.

29.

Mestre

, Fereshtehnejad

, Berg

, Bohnen

, Dujardin

, Erro

, Espay

, Halliday

, van Hilten

, Hu

, Jeon

, Klein

, Leentjens

AFG

, Marinus

, Mollenhauer

, Postuma

, Rajalingam

, Rodríguez-Violante

, Simuni

, Surmeier

, Weintraub

, McDermott

, Lawton

, Marras

(2021) Parkinson’s disease subtypes: Critical appraisal and recommendations. J Parkinsons Dis 11, 395–404.

30.

Lawton

, Ben-Shlomo

, May

, Baig

, Barber

, Klein

, Swallow

DMA

, Malek

, Grosset

, Bajaj

, Barker

, Williams

, Burn

, Foltynie

, Morris

, Wood

, Grosset

, Hu

MTM

(2018) Developing and validating Parkinson’s disease subtypes and their motor and cognitive progression. J Neurol Neurosurg Psychiatry 89, 1279–1287.

31.

Aarsland

, Brønnick

, Alves

, Tysnes

, Pedersen

, Ehrt

, Larsen

(2009) The of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease. J Neurol Neurosurg Psychiatry 80, 928–930 spectrum.

32.

Liu

, Lawton

, Lo

, Bowring

, Klein

, Querejeta-Coma

, Scotton

, Welch

, Razzaque

, Barber

, Ben-Shlomo

, Hu

(2021) Longitudinal changes in Parkinson’s disease symptoms with and without rapid eye movement sleep behavior disorder: The Oxford Discovery Cohort Study. Mov Disord 36, 2821–2832.

33.

Bódi

, Kéri

, Nagy

, Moustafa

, Myers

, Daw

, Dibó

, Takáts

, Bereczki

, Gluck

(2009) Reward-learning and the novelty-seeking personality: A between- and within-subjects study of the effects of dopamine agonists on young Parkinson’s patients. Brain 132, 2385–2395.

34.

Menza

, Mark

, Burn

, Brooks

(1995) Personality correlates of [18F]dopa striatal uptake: Results of positron-emission tomography in Parkinson’s disease. J Neuropsychiatry Clin Neurosci 7, 176–179.

35.

Maillet

, Krack

, Lhommée

, Météreau

, Klinger

, Favre

, Le Bars

, Schmitt

, Bichon

, Pelissier

, Fraix

, Castrioto

, Sgambato-Faure

, Broussolle

, Tremblay

, Thobois

(2016) The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson’s disease. Brain 139, 2486–2502.

36.

Koerts

, Tucha

, Leenders

, Tucha

(2013) Neuropsychological and emotional correlates of personality traits in Parkinson’s disease. Behav Neurol 27, 567–574.

37.

Damholdt

, Ostergaard

, Borghammer

, Larsen

(2011) The parkinsonian personality and concomitant depression. J Neuropsychiatry Clin Neurosci 23, 48–55.

38.

Pluck

, Brown

(2002) Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 73, 636–642.

39.

Berridge

, Robinson

(2016) Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol 71, 670–679.

40.

Petitet

, Scholl

, Attaallah

, Drew

, Manohar

, Husain

(2021) The relationship between apathy and impulsivity in large population samples. Sci Rep 11, 4830.

41.

Pontone

, Mari

, Perepezko

, Weiss

, Bassett

(2017) Personality and reported quality of life in Parkinson’s disease. Int J Geriatr Psychiatry 32, 324–330.